Answers are grounded in this paper and cite their sources.
Evaluates chalcogen-phosphoranes' antimalarial effects, suggesting potential for drug development.
Malaria remains a major global health challenge with growing resistance to current antimalarial drugs. In this study, we report the antiplasmodial activity of eight sulfur-containing chalcogen-phosphorane analogues that show submicromolar potency against Plasmodium falciparum 3D7 strain (IC50s = 0.7–1.9 μM) and reasonable selectivity indexes (SI) over HepG2 and HEK293 cells (SI ≥ 12). Electron-withdrawing substituents on the aromatic ring improved potency by two- to 3-fold. Compound 5, a representative compound of the series, showed fast-acting inhibitory activity that rapidly induced pyknotic nuclei, demonstrated no cross-resistance with standard antimalarials, and exhibited an additive interaction with artesunate. Stage-specific assays revealed pronounced activity against ring and trophozoite stages but reduced efficacy against schizonts, with longer exposure needed for maximal effects. In a murine Plasmodium berghei model, compound 5 showed modest in vivo activity but slightly improved the survival rate. These findings suggest that sulfur-containing chalcogen-phosphoranes represent an attractive series for hit-to-lead development.
No takes yet. Share an insight, caveat, or question.
Moura et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: